Helix BioPharma mulls WSE debut

Helix BioPharma, a Canadian pharmaceutical firm with Polish sharholders, may carry out an IPO on the Warsaw Stock Exchange within the next 12 months, the company’s CEO Robert Verhagen told daily Parkiet. The company is now listed in Toronto and in Frankfurt. “We don’t just want another dual listing. If the WSE debut goes through, we will carry out a public offering of share,” Verhagen said. “We are also considering other markets and other ways of raising capital.” According to Bloomberg data, three Polish businessmen are shareholders of Helix BioPharma.  Sylwester Cacek has a 4.6 percent stake, Marek Orłowski holds 2.3 percent and Sławomir Majewski holds 2.3 percent. They are all members of the firm’s board of directors.